問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭昶甫

Recruiting

List

18Cases

2025-05-01 - 2026-01-30

Phase I

Active
A Dose Escalation Study of IG3018 to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics in Subjects with Hyperuricemia with or without Chronic Kidney Disease

  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    tablet

Participate Sites
4Sites

Recruiting4Sites

2021-10-01 - 2028-07-07

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-06-01 - 2026-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting3Sites

Recruiting7Sites

2019-07-04 - 2022-05-31

Phase II

Completed
A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    Elsubrutinib, Upadacitinib

Participate Sites
6Sites

Recruiting6Sites

2018-08-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2021-07-09 - 2026-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-07-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-09-10 - 2026-10-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-08-27 - 2023-12-18

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis

  • Condition/Disease

    Active Lupus Nephritis

  • Test Drug

    Guselkumab

Participate Sites
4Sites

Recruiting4Sites

2019-04-01 - 2025-12-31

Phase II

Modeling the relationships between functional connectivity and amyloid deposition in Alzheimer’s disease

  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    F-18 AV-45

Participate Sites
2Sites

Recruiting2Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB